Lisa Miller

Immunotherapies have been tested in melanoma, breast, prostate, kidney, and lung cancers, and are now being studied in advanced gastric cancers.

Immunohistochemistry can effectively be used for the identification of ROS1 gene alterations to ascertain eligibility for the targeted therapy crizotinib for patients with non-small cell lung cancer.